Long-term impact of aficamten on patient-reported outcome measures in obstructive hypertrophic cardiomyopathy: results from FOREST-HCM.

What was studied

This study followed people with obstructive hypertrophic cardiomyopathy who took aficamten. It was an open-label extension of earlier trials. 172 people finished at least 48 weeks. They filled in questionnaires on health, symptoms and quality of life. Scores were taken again at later visits, up to week 48.

What they found

All questionnaire scores improved by week 12. They stayed better through week 48. At week 48, the overall Kansas City questionnaire score rose by 18.8 points. The biggest gain was in the quality of life part, at 25.8 points. Angina questionnaire scores rose by 17.2 points. The EuroQol index rose 0.11, and its visual scale rose 12.7 points. Better scores were linked to clinical markers of disease severity.

What it means for patients

The authors say aficamten led to lasting gains across several areas of health status. They say these gains tracked clinical markers of how severe the disease is.

Why it is not certain yet

Everyone knew they were taking the drug, since the study was open-label. The abstract describes no comparison group. Only people who finished 48 weeks were included. A link between scores and markers does not show cause.

Source

Long-term impact of aficamten on patient-reported outcome measures in obstructive hypertrophic cardiomyopathy: results from FOREST-HCM.

We restate facts from the source record in our own words. The original wording belongs to its publisher.